**Instructions:** This is a sample study exit script for exiting MTN-015 participants who enrolled from the ASPIRE or HOPE parent protocol. Sites are to modify this text as needed based on site specific information/practices. This sheet is a reference for study staff to provide information relevant to the end of MTN-015 and does not need to be read verbatim and should not be provided in written form to the study participants.

Before we finish your visit today, I would like to take some time to sincerely thank you for taking part in this study. By taking part, you have made an important contribution to the fight against HIV/AIDS. *[Sites to modify as needed: In recognition of this contribution, I would like to present you with this certificate of completion which you can take with you today.]* I also would like to review a few more details with you:

* Your appointment to receive your final test results is scheduled for *[date]*. This appointment will take place [*here at the clinic / other specify*]. If you need to change this appointment for any reason, please contact us to let us know. *[If applicable, reinforce plans for clinical care follow-up*.]
* The study is ending because researchers have collected enough follow-up information to answer the study questions. All MTN-015 participants will exit the study by 30JUN2019.
* I would like to share with you the results we have from the MTN-015 study to date that are relevant to former ASPIRE/HOPE participants. Among participants enrolled from the ASPIRE/MTN-020 trial:
  + **Dapivirine ring use did not impact HIV disease progression.**  In other words, the health of women after their HIV infection was similar regardless of whether they used the dapivirine or placebo ring around the time of their HIV infection.
  + **Dapivirine ring use did not impact the effectiveness of medications similar to dapivirine that are used to treat HIV**.  In other words, the bodies of women responded the same to HIV treatment regardless of whether they used the dapivirine or placebo ring around the time of their HIV infection.
  + **Dapivirine ring use did not cause HIV drug resistance.**  There was no difference in the frequency of drug resistance between dapivirine and placebo groups. Drug resistance is when one or more medicines that usually work to treat HIV, called antiretrovirals or ARVs, no longer work as well.
* You will be contacted if results change significantly based on additional analysis of MTN-015 data. In order for us to share any updated results, we need to be able to keep in touch with you. Therefore, we ask you to please inform us if you move to a new home, change your phone number, or have any other new details that would help us keep in touch with you. *[Sites to modify as needed: Give contact card.]*
* The most important results for your health care are the measurements of immune cells and HIV level in your blood. These test results can be given to you or to your doctor with your permission.
* Lastly, we would like to give you some information on places where you can go for different types of services now that you will not be coming here for regular study visits *[sites to modify as needed: give referral sheet]:*
* For HIV wellness care and counseling
* For antiretroviral treatment
* For PMTCT
* For counseling related to infant feeding
* For contraception and other reproductive health care
* For other types of health care
* Other

Please feel free to contact us if you have any questions about the study that we have not answered today, or if you have any problems related to your participation in the study. Once again, we sincerely thank you for your contributions to the study.